- Home
- RNAZ vs RDHL Comparison
RNAZ vs RDHL Comparison
Compare RNAZ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAZ | RDHL |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | Israel |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.2M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RNAZ | RDHL |
|---|---|---|
| Price | $3.38 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 36.0K |
| Earning Date | 04-15-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $0.58 |
| 52 Week High | $20.99 | $2.79 |
Technical Indicators
Market Signals| Indicator | RNAZ | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 36.35 |
| Support Level | N/A | N/A |
| Resistance Level | $6.15 | $0.91 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 3.58 | 0.20 |
Price Performance
Historical ComparisonAbout RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.